Introduction Kidney and liver transplantation substantially improve survival and quality of life in patients with end-stage organ disease. However, cardiovascular disease (CVD) remains a leading cause of long-term morbidity and premature mortality after transplantation.
Introduction
Kidney and liver transplantation substantially improve survival and quality of life in patients with end-stage organ disease. However, cardiovascular disease (CVD) remains a leading cause of long-term morbidity and premature mortality after transplantation. Despite successful graft function, transplant recipients continue to face a substantial burden of cardiovascular complications that extends well beyond the peri-transplant period.
Problem Statement
Although transplantation reduces mortality compared with dialysis or untreated end-stage liver disease, it does not eliminate cardiovascular risk. Kidney and liver transplant recipients remain vulnerable to a broad spectrum of cardiac disorders, including coronary artery disease, heart failure, arrhythmias, valvular disease and pulmonary hypertension. This persistent risk reflects the combined effects of pre-existing cardiometabolic disease, transplant-related metabolic injury and chronic exposure to immunosuppressive therapy, creating a complex and often under-recognized cardiovascular burden.
Summary
This review highlights the persistent and multifactorial cardiovascular risk faced by kidney and liver transplant recipients, emphasizing that transplantation should be viewed as a transition to chronic cardiovascular risk management rather than risk resolution. The authors describe how pre-transplant vascular disease is compounded after transplantation by weight gain, dyslipidaemia, diabetes, hypertension and immunosuppression-related metabolic toxicity, resulting in sustained cardiovascular vulnerability. Importantly, this risk spans multiple cardiac phenotypes, including ischemic heart disease, heart failure, arrhythmias, valvular dysfunction and pulmonary vascular disease, each requiring organ-specific clinical consideration. The review underscores that cardiovascular surveillance in transplant recipients must extend beyond traditional risk assessment and incorporate longitudinal, multidisciplinary care tailored to graft type and metabolic profile. A central message is that long-term transplant success depends not only on graft survival, but also on proactive cardiovascular prevention, early recognition of evolving cardiac disease and coordinated management across transplant, cardiology and metabolic care teams.
Introduction: Bacterial infections remain a major cause of morbidity after liver transplantation despite advances in perioperative care. Synbiotics, combining probiotics and prebiotics, have been proposed to reduce postoperative infections by restoring gut microbiota and strengthening...
Introduction: Perioperative bleeding remains a major challenge during orthotopic liver transplantation (OLT), largely due to hyperfibrinolysis and coagulation abnormalities. Although tranexamic acid (TXA) effectively reduces bleeding in several surgical settings, its routine prophylactic use during...
Introduction: Liver transplantation is limited by a shortage of suitable donor organs. Current viability assessment relies on needle biopsy, which samples only a small portion of the liver and may miss important regional pathology. This...
Introduction: Bleeding remains a major challenge during liver transplantation despite advances in surgical techniques, anesthesia, and perioperative care. Antifibrinolytic agents have long been used to reduce intraoperative blood loss and transfusion requirements. However, evolving transplant...
Introduction: The demand for liver transplantation continues to exceed the availability of deceased donor organs, resulting in prolonged waiting times and preventable waitlist mortality. This perspective discusses how living donor liver transplantation (LDLT) can complement...
Introduction: Pediatric liver transplantation has achieved excellent survival rates, shifting the focus from graft survival alone to optimising long-term health, growth, neurodevelopment, and quality of life. This updated guideline provides evidence-based recommendations for comprehensive care...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.